兴齐眼药：第三季度净利润2.64亿元 同比增长117.45%

Core Viewpoint - Xingqi Eye Pharmaceutical (300573) reported strong financial performance for Q3 2025, with significant growth in both revenue and net profit driven by increased sales of eye drop products [1] Financial Performance - Q3 2025 revenue reached 741 million yuan, representing a year-on-year increase of 35.34% [1] - Q3 2025 net profit was 264 million yuan, showing a year-on-year growth of 117.45% [1] - For the first three quarters of 2025, total revenue was 1.904 billion yuan, up 32.27% compared to the same period last year [1] - Net profit for the first three quarters of 2025 amounted to 599 million yuan, reflecting a year-on-year increase of 105.98% [1] - Basic earnings per share for the first three quarters were 2.44 yuan [1] Product Performance - The growth in revenue for the first three quarters was primarily attributed to the increase in sales revenue from eye drop products [1]